TapewireFind a company

person · Reporting owner

Young Teresa L.

Disclosed activity across 1 company

Tapewire entity
65846
SEC CIK
0001814656

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Seres Therapeutics, Inc.MCRB · Entity 7191See RemarksFebruary 15, 2026February 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Seres Therapeutics, Inc.

Report date February 15, 2026 · Filed February 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect8,557 Ending reported balance After 2026-02-15 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-15 · Exercise / conversion · Acquired 231 · Balance 8,632

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Row 2 · 2026-02-15 · Sale · Disposed 75 · Balance 8,557

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect531 Reported balance After 2026-02-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-15 · Exercise / conversion · Disposed 133 · Balance 531

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect780 Reported balance After 2026-02-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-02-15 · Exercise / conversion · Disposed 98 · Balance 780

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 15, 2026 Filed Feb 18, 2026 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 98 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-057157 · ownership.xml · derivative · entry 4

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 780

Underlying: Common Stock · 98 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 133 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-057157 · ownership.xml · derivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 531

Underlying: Common Stock · 133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 75 $8.47 $635.25
Disclosure

SEC source: 0001193125-26-057157 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,557

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 231 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-057157 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,632

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
November 15, 2025 Filed Nov 18, 2025 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 98 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-286236 · ownership.xml · derivative · entry 7

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 878

Underlying: Common Stock · 98 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F5 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F5 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
November 15, 2025 Filed Nov 18, 2025 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 132 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-286236 · ownership.xml · derivative · entry 6

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 664

Underlying: Common Stock · 132 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
November 15, 2025 Filed Nov 18, 2025 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 3,998 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-286236 · ownership.xml · derivative · entry 5

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,998 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date.

F3 · derivative.expiration_date: The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date.

Read SEC document
November 15, 2025 Filed Nov 18, 2025 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 1,042 $17.30 $18,026.60
Disclosure

SEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 4

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,401

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Read SEC document
November 15, 2025 Filed Nov 18, 2025 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 98 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,443

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

Read SEC document
November 15, 2025 Filed Nov 18, 2025 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 132 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

Read SEC document
November 15, 2025 Filed Nov 18, 2025 21:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 3,998 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

Read SEC document
September 26, 2025 Filed Sep 30, 2025 20:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantRestricted Stock Units · Derivative 3,998 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-225105 · ownership.xml · derivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,998

Underlying: Common Stock · 3,998 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date.

F2 · derivative.expiration_date: The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 20:06 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 59 $16.65 $982.35
Disclosure

SEC source: 0001193125-25-183434 · ownership.xml · nonDerivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,215

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:06 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 97 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-183434 · ownership.xml · derivative · entry 5

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 976

Underlying: Common Stock · 97 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:06 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 133 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-183434 · ownership.xml · derivative · entry 4

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 796

Underlying: Common Stock · 133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:06 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 97 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-183434 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,274

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:06 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 133 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-183434 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,177

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
May 16, 2025 Filed May 19, 2025 20:05 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 63 $7.28 $458.64
Disclosure

SEC source: 0000950170-25-074328 · ownership.xml · nonDerivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,044

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025.

Read SEC document
May 15, 2025 Filed May 19, 2025 20:05 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 98 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-074328 · ownership.xml · derivative · entry 5

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,073

Underlying: Common Stock · 98 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F5 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F5 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025.

Read SEC document
May 15, 2025 Filed May 19, 2025 20:05 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 133 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-074328 · ownership.xml · derivative · entry 4

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 929

Underlying: Common Stock · 133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025.

Read SEC document
May 15, 2025 Filed May 19, 2025 20:05 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 98 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-074328 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025.

Read SEC document
May 15, 2025 Filed May 19, 2025 20:05 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 133 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-074328 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 01:11 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 3,338 $0.81 $2,704.45
Disclosure

SEC source: 0000950170-25-023584 · ownership.xml · nonDerivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,536

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.832001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:11 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 7,813 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-023584 · ownership.xml · derivative · entry 5

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,437

Underlying: Common Stock · 7,813 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F5 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F5 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:11 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 2,657 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-023584 · ownership.xml · derivative · entry 4

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,250

Underlying: Common Stock · 2,657 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:11 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 7,813 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-023584 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,874

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:11 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 2,657 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-023584 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
February 07, 2025 Filed Feb 11, 2025 21:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 650,000 $0.00 Strike: $0.78 $0.00
Disclosure

SEC source: 0000950170-25-017913 · ownership.xml · derivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2035-02-06

F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Read SEC document
November 18, 2024 Filed Nov 19, 2024 21:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 735 $0.54 $397.64
Disclosure

SEC source: 0000950170-24-128613 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,404

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $ 0.5638, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 2,656 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-128613 · ownership.xml · derivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,907

Underlying: Common Stock · 2,656 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 2,656 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-128613 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,139

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
October 28, 2024 Filed Oct 29, 2024 22:23 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 2,983 $0.69 $2,058.57
Disclosure

SEC source: 0000950170-24-118405 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,483

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 18, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F4 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.6934, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 27, 2024 Filed Oct 29, 2024 22:23 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 11,360 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-118405 · ownership.xml · derivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,360 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date.

F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

Read SEC document
October 27, 2024 Filed Oct 29, 2024 22:23 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 11,360 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-118405 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,466

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date.

F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

Read SEC document
August 16, 2024 Filed Aug 19, 2024 21:36 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 728 $0.84 $611.52
Disclosure

SEC source: 0000950170-24-098710 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,106

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:36 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 2,656 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-098710 · ownership.xml · derivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,563

Underlying: Common Stock · 2,656 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:36 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 2,656 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-098710 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,834

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
August 05, 2024 Filed Aug 6, 2024 20:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 24,480 $1.08 $26,533.87
Disclosure

SEC source: 0000950170-24-091832 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,178

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.1101, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 03, 2024 Filed Aug 6, 2024 20:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 85,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-091832 · ownership.xml · derivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 85,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units vested and settled as to 100% of the restricted stock units on August 3, 2024.

F4 · derivative.expiration_date: The restricted stock units vested and settled as to 100% of the restricted stock units on August 3, 2024.

Read SEC document
August 03, 2024 Filed Aug 6, 2024 20:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 85,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-091832 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,658

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
May 15, 2024 Filed May 18, 2024 00:18 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 2,656 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-062058 · ownership.xml · derivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,219

Underlying: Common Stock · 2,656 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
May 15, 2024 Filed May 18, 2024 00:18 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 703 $0.94 $660.82
Disclosure

SEC source: 0000950170-24-062058 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,658

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 15, 2024 Filed May 18, 2024 00:18 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 2,656 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-062058 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,361

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
February 16, 2024 Filed Feb 17, 2024 02:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 3,374 $1.08 $3,643.92
Disclosure

SEC source: 0000950170-24-016694 · ownership.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,705

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 15, 2024 Filed Feb 17, 2024 02:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 10,625 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 6

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,875

Underlying: Common Stock · 10,625 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F7 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F7 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 15, 2024 Filed Feb 17, 2024 02:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 10,625 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-016694 · ownership.xml · nonDerivative · entry 1

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,079

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
February 14, 2024 Filed Feb 17, 2024 02:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantRestricted Stock Units · Derivative 31,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 5

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F6 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F6 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 14, 2024 Filed Feb 17, 2024 02:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 287,905 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 4

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 287,905

Underlying: Common Stock · 287,905 shares

Expires 2034-02-13

F5 · derivative.exercise_date: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.

Read SEC document
February 14, 2024 Filed Feb 17, 2024 02:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 187,500 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 3

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2034-02-13

F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 01:40 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 2,907 $1.35 $3,924.45
Disclosure

SEC source: 0000899243-23-020079 · doc4.xml · nonDerivative · entry 2

Young Teresa L. · CIK 0001814656 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,454

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 18, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.

F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.